Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $80.00 price target on the stock.
Belite Bio, Inc (NASDAQ: BLTE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website [Yahoo! Finance]